Chief Strategy Officer — Commercial Launch Organisation

The mandate

A commercial launch organisation is expanding its portfolio across multiple geographies. Several potential launches now compete for investment, country capacity and specialist support. The board has created a new Chief Strategy Officer role to make choices that balance growth ambition with controlled execution.

Approximately 675 employees and material partners span commercial, medical, market access, regulatory, operations, finance and enabling functions from Dublin across international markets. The CSO owns launch portfolio strategy, investment cases, scenarios, partnerships and enterprise planning, reporting to the Group Chief Executive or nominated sponsor. Quality, medical and regulatory functions retain independent approval.

The opening task is to rebuild each launch thesis with controlled evidence. Label scenarios, patient population, differentiation, access, supply, claims and capability must connect. The CSO will identify assumptions that remediation findings have weakened and state what evidence restores confidence.

Launch sequence will reflect both opportunity and control maturity. A commercially attractive market may not be ready if content, consent, distribution or adverse-event intake remains weak. The CSO will recommend waves and gates that integrate regulatory, quality and operational readiness, with authority to pause investment.

Portfolio capital needs explicit trade-offs. Field teams, patient programmes, digital platforms, evidence and inventory all compete for funds. The strategy office will show marginal value, critical lead time and reversibility. Every added priority must identify what stops or moves later.

Claims and positioning are strategic constraints, not only review tasks. If evidence supports a narrower narrative, forecasts and operating design must change. The CSO will not preserve value by assuming future analyses will justify the preferred proposition.

Market access requirements should influence launch and evidence decisions early. Comparative, economic, pathway and implementation evidence vary by country. The CSO will identify common assets and local gaps, avoiding duplicated research while recognising legitimate market differences.

Quality remediation investments require a future-state view. Additional reviewers, systems and consultants may be necessary now, but should not become permanent burden by default. The CSO will ensure control design scales with the portfolio and has clear handback, cost and effectiveness measures.

Partnership may offer a better route in markets where internal capability or control maturity is weak. The CSO will evaluate distributors, co-commercial partners and regional licences on economics, conduct, data, safety, quality and exit. A partner's reach cannot substitute for governable execution.

Country readiness will be challenged through evidence. Local plans should show payer route, supply, trained teams, approved material, vendor and escalation. Green status based on planned completion will be distinguished from proven operation. The CSO will identify cross-market dependencies that local leaders cannot solve alone.

Downside scenarios are mandatory. Delayed approval, restricted label, payer refusal or remediation extension should trigger pre-agreed changes in spend, hiring and market sequence. Commitments with poor cancellation value require higher confidence. Strategy should preserve choice without leaving teams directionless.

Benefits and forecasts will use common assumptions. The organisation currently maintains separate development, commercial and finance versions. The CSO will establish one register with owner, source and update. Differences should be intentional and visible, not reconciled only before a board meeting.

The strategy team will remain small and decisive. It will own thesis, choices and review triggers; operating executives will deliver. If implementation evidence contradicts the case, strategy will revisit the decision rather than defend its model. Success is funded action and stopped activity.

What you will own

• Launch portfolio thesis and sequencing.
• Evidence, control and readiness integration.
• Capital allocation and scenario triggers.
• Market access and country strategy.
• Quality-remediation future state.
• Commercial partnerships and market routes.
• Board choices and assumption integrity.
• Strategy talent and succession.

The first 12 months

Within 45 days, rebuild priority launch cases, identify assumptions invalidated by remediation and freeze irreversible commitments lacking evidence. Present alternatives to the board.

By month six, approve launch waves, capital and control future state. Decide partnership markets and stage commitments against explicit triggers.

At twelve months, reallocate 20% of launch capital towards higher-confidence markets or assets, complete 95% of board decisions within 30 days of trigger evidence and reduce duplicated remediation or launch investment by 25%. Every first-wave market must pass integrated control and operating gates before external activation.

What the sponsor will examine

• Launch cases reflecting remediation evidence.
• Country waves based on control and market readiness.
• Capital additions accompanied by explicit stops.
• Claims constraints changing forecasts honestly.
• Temporary remediation capacity designed to exit.
• Partnerships assessed for governed execution.

The person

You bring 22–28 years in pharmaceutical strategy, commercialisation, market access or portfolio leadership. Your record includes launch sequencing during quality remediation, international capital choices and board decisions under label or approval uncertainty.

Candidates must show an attractive launch they delayed because control evidence failed and an investment they stopped. The permanent onsite role is based in Dublin with international market and partner engagement.

Compensation and terms

Base compensation is EUR 285,000–390,000 plus annual incentive and long-term participation linked to launch value, capital choices, remediation, decision pace and leadership. Based onsite at the Dublin operating centre, this permanent executive answers to the Group Chief Executive or the appointed executive-committee sponsor. The new role is urgent before the next investment cycle.

Confidentiality

The enterprise, assets, evidence, quality findings, markets, partners, forecasts and portfolio choices remain confidential. Further information follows conflicts and signed confidentiality. Applicants must not contact companies or advisers to infer the client.